Email
Print
Companion Diagnostic Tests In Oncology Market - Forecast(2024 - 2030)
Oncology Market Overview
Companion Diagnostic Tests In Oncology Market size is
estimated to reach $5.5 billion by 2027, growing at a CAGR of 12.2% during the
forecast period 2022-2027. Companion Diagnostic Tests condense anguish progress
consequences, use an efficacious therapeutic drug and procedure for patient’s
misery from cancer. Outdated therapies were directed to patients based on the
lumpy and general diagnosis. In the contemporary world Illnesses like oncology
is separated into detailed categories such as Thoracic oncology (= Chest,
lungs cancer), RCC, UC, etc. to provide meticulous resolution. Nowadays by
means of genomic technologies such as, “Companion Biomarkers” (= running
therapies on a biological molecule found in the blood) doctors can illustrate
profile, diseases to punctilious aching, and the accurate rehabilitation that
is going to be utmost efficacious for the patient. Similarly, for the sickness
specialists can recognize the accurate prescription and treatment extent. This
means that Patients can circumvent prolonged recapitulations of futile
medicines being used on patients frequently with unfavorable effects.
Diagnostics nowadays are vividly cast-off and applied as a resolution to healthcare complications. The investments in info apparatuses and machinery is set to drive the growth of the Companion Diagnostic Tests in the Oncology Industry
for the period 2022-2027.
Report Coverage:
The report: “Companion Diagnostic Tests In Oncology Market Forecast (2022-2027)”, by Industry
ARC, covers an in-depth analysis of the following segments of the Companion Diagnostic Tests In Oncology Market.
By
Application: Oncology, Congenital/Neurological
ailments, Respiratory and Vascular ailments, transmissible sicknesses, etc.
By Technology:
NGS, FISH, PCR, IHC, and Biomarker testing.
By End User: Laboratories,
Hospitals, Health Centers, CRO, Pharma companies.
By Geography:
North America (U.S., Canada, and Mexico), Europe (Germany, UK, France, Italy,
Spain, Russia, and Rest of Europe), Asia-Pacific (China, India, Japan, South
Korea, Australia & New Zealand, and Rest of Asia-Pacific), South America
(Brazil, Argentina, and Rest of South America) and Rest of World (the Middle
East and Africa).
Key Takeaways:
- Geographically, the Asia- Pacific Companion Diagnostic Tests In Oncology Market accounted for the highest revenue share in 2021. In addition to that, Asia-Pacific is poised to dominate the market over the period 2022-2027 owing to the gigantic population which is still intensifying and resulting in a swell in an assortment of ailments.
- The unprecedented swell in the number of people inflicted with some sort of cancer-driving the Diagnostic Tests in Oncology Market. However, the extortionate cost of the associated treatments is one of the major factors that are said to reduce the growth of the Companion Diagnostic Tests in the oncology market.
- Detailed analysis on the Strength, Weaknesses, and
Opportunities of the prominent players operating in the market will be provided
in the Companion Diagnostic Tests In Oncology Market report.
Companion Diagnostic Tests In Oncology Market Share, By End User, 2021(%)
For More Details on This Report - Request for Sample
Companion Diagnostic Tests In Oncology Market Segment Analysis-By Technology
The Companion Diagnostic Tests In Oncology Market based on
the Technology can be further segmented into NGS (= next-generation
sequencing), FISH (= fluorescence in situ hybridization), PCR (= polymerase
chain reaction), IHC (= Immunohistochemistry), Biomarker testing. The PCR (=
polymerase chain reaction) segment held the largest share in 2021 owing to the
factors such as upsurge in COVID-19 cases throughout the world has ensued into
gargantuan RT-PCR testing in order to exterminate the virus, widespread
availability, and easy to use nature, high precision degree. As per recent
reports, COVID-19 has gripped around 265 million of the global
population, which has taken the lives of around 5 million. Owing to better testing
facilities, the spread has been catered to limited populations.
Moreover, the PCR (= polymerase chain reaction) segment is
estimated to be the fastest-growing segment with a CAGR of 12.9% over the
period 2022-2027. This growth is owing to the low-price equivalent to other
diagnostic procedures along with its reasonable accuracy, increasing awareness
has made people realize that “prevention is better than cure.”
Companion Diagnostic Tests In Oncology Market Segment Analysis-By End User
The Companion Diagnostic Tests In Oncology Market based on
the End User can be further segmented into Laboratories, Hospitals, Health
Centres, CROs (=Clinical research Organizations), Pharma companies. The
Pharmaceutical segment held the largest share in 2021 owing to factors such due
to unconceivable demand as they are the first point of contact for other health
establishments like laboratories, hospitals for materials required to run
diagnostic techniques on patients, a technological breakthrough in research and
developments of various medicines and apparatuses or machines in the medical
field. Giant pharma players such as Incyte saw an increase in their R&D
allocation from $1.3 billion to $2.13 billion in 2020. Owing to such a surge, the
segment held a dominant share.
The Contract Research Organizations segment is estimated to be the fastest-growing segment with a CAGR of 13.1% over the forecast period 2022-2027. This growth is owing to new drug discoveries, technological advancements in tolls and techniques required in the diagnosis process, massive spending on R&D by both developed and developing nations. Additionally, private players are commissioning new contracts with CROs to save the overhead costs and the rising need for expertise.
Companion Diagnostic Tests In Oncology Market Segment Analysis-By Geography
The Companion Diagnostic Tests in oncology based on Geography can be further segmented into North America, Europe, Asia-Pacific, South America, and the Rest of the World. Asia-Pacific held the largest share with 37% of the overall market in 2021. The growth in this segment is owing to the factors such as colossal population in developing countries like India and China, which is still anticipated to escalate in positive custom in forthcoming years. The growing economies of countries are opening ways to invest more in research and development, production of top-flight researcher and engineers, growing health cognizance among inhabitants of the region, unbelievable sell in COVID-19 cases especially in countries like India, Nepal, and China, weaker immunity of poor section of people due to deprived living conditions is having an enormous affluence slit in countries like India, skyrocketing exports of pharmaceutical. Additionally, in 2050, the ratio of people aged 15-64 to people aged over 65 years will be around one-third of the 2020 value in high-income Asia-Pacific countries.
Companion Diagnostic Tests In Oncology Market Drivers
Swelling causes of cancer and other ailments is Projected to Drive Market Growth
Viruses’ diseases are spreading across the globe on an unprecedented
scale which the world has never seen before. New viruses are spiraling, their
altering characteristics and constant mutation have posed a big threat in front
of the medical industry. Viruses like Bird Flu which used to proliferate only
among birds, now after mutating are transmissible into humans also. Around
1,900,000 patients were diagnosed with cancer, and approximately 600,000
individuals lost their lives in the US.
Technological advancement and more investments in the medical field are Expected to Boost Product Demand
As transmissible, cancer and other sicknesses are prevailing
in every part of the world, countries have their quests in discovering
breakthroughs for these ailments with enormous disbursement of riches into
medical explorations and development discipline which is ensuing into foremost
gears and procedures to fight with diseases. The readiness of technologies such
as NGS, FISH, IHC, RT-PCR, and Biomarker testing has made their noteworthy
contribution in medical especially in diagnoses of ailments.
Companion Diagnostic Tests In Oncology Market Challenges
The innumerable cost of such procedures is Anticipated to Hamper Market Growth
The obligation of Gargantuan outlay is to diagnose various
communicable sicknesses and cancer. State-of-the-art treatments like FISH, NGS,
IHC can cost an arm and leg which makes the middle-class population as aversive
as ever to go for these procedures. Other than that, it’s not an easy fix to
set up a laboratory equipped with such facilities. Hospitals, labs have to
invest an enormous amount of money for acquiring the machinery, building the
facility, hiring professionals with an adequate amount of knowledge.
Companion Diagnostic Tests In Oncology Industry Outlook
Product launches, mergers and acquisitions, joint ventures,
and geographical expansions are key strategies adopted by players in the
Companion Diagnostic Tests in the oncology market. The top-10 Key companies of
this Companion Diagnostic Tests in the oncology market are-
- QIAGEN
- Abbott
- Illumina
- Agilent
- Roche
- Agendia
- Genomic Health
- Siemens Healthcare
- BioMerieux
- Roche Diagnostics
Partnerships/Product
Launches:
- On November 5, 2021, Veracyte a diagnostic firm proclaimed that the company’s test which is known as, “Immunoscore Colon” for cancer treatment has been encompassed all over the Asian continent. the test is really supportive in checking immune responses by the patient’s body at the tumor site. Veracyte acquired the Immunoscore Colon Cancer test through its acquisition of HalioDx in August 2021. The test measures the patient immune response at the tumor site and is used to inform chemotherapy decision-making for patients with Stage II and III colon cancer.
- On October 18, 2021, a New Jersey-based clinical laboratory, “Quest Diagnostics” announced that the company will soon propose the first-ever companion Diagnostic named as, “Ki-67 IHC MIB-1 pharmDx” for the company Eli Lilly and an inhibitor for the patients suffering from High-risk breast cancer. Ki-67 is a marker of cellular proliferation. Verzenio is the first and only CDK4/6 inhibitor approved for this patient population.
- On October 12, 2021, North Carolina-based firm GeneCentric Therapeutics collaborated with a global life sciences company named Labcorp in order to Develop RNA (=Ribonucleic acid) based Oncology Diagnostics which the world has never seen before. If a breakthrough gets achieved, it could provide assistance in deeper insights into cancer. RNA-based gene signatures provide deeper insights into the tumor and immune micro-environment when compared to traditional DNA testing. They can be used to identify a broader patient population that may benefit from targeted or immunotherapy.
Relevant Links:
HIV Diagnosis Market – Forecast
(2022 - 2027)
Report Code: HCR 64783
Brain Tumor Treatment Market –
Forecast (2022 - 2027)
Report Code: HCR 0257
For more Chemicals and Materials Market reports, please click here
Table1: Companion Diagnostic Tests in Oncology Market Overview 2023-2030
Table2: Companion Diagnostic Tests in Oncology Market Leader Analysis 2023-2030 (US$)
Table3: Companion Diagnostic Tests in Oncology Market Product Analysis 2023-2030 (US$)
Table4: Companion Diagnostic Tests in Oncology Market End User Analysis 2023-2030 (US$)
Table5: Companion Diagnostic Tests in Oncology Market Patent Analysis 2013-2023* (US$)
Table6: Companion Diagnostic Tests in Oncology Market Financial Analysis 2023-2030 (US$)
Table7: Companion Diagnostic Tests in Oncology Market Driver Analysis 2023-2030 (US$)
Table8: Companion Diagnostic Tests in Oncology Market Challenges Analysis 2023-2030 (US$)
Table9: Companion Diagnostic Tests in Oncology Market Constraint Analysis 2023-2030 (US$)
Table10: Companion Diagnostic Tests in Oncology Market Supplier Bargaining Power Analysis 2023-2030 (US$)
Table11: Companion Diagnostic Tests in Oncology Market Buyer Bargaining Power Analysis 2023-2030 (US$)
Table12: Companion Diagnostic Tests in Oncology Market Threat of Substitutes Analysis 2023-2030 (US$)
Table13: Companion Diagnostic Tests in Oncology Market Threat of New Entrants Analysis 2023-2030 (US$)
Table14: Companion Diagnostic Tests in Oncology Market Degree of Competition Analysis 2023-2030 (US$)
Table15: Companion Diagnostic Tests in Oncology Market Value Chain Analysis 2023-2030 (US$)
Table16: Companion Diagnostic Tests in Oncology Market Pricing Analysis 2023-2030 (US$)
Table17: Companion Diagnostic Tests in Oncology Market Opportunities Analysis 2023-2030 (US$)
Table18: Companion Diagnostic Tests in Oncology Market Product Life Cycle Analysis 2023-2030 (US$)
Table19: Companion Diagnostic Tests in Oncology Market Supplier Analysis 2023-2030 (US$)
Table20: Companion Diagnostic Tests in Oncology Market Distributor Analysis 2023-2030 (US$)
Table21: Companion Diagnostic Tests in Oncology Market Trend Analysis 2023-2030 (US$)
Table22: Companion Diagnostic Tests in Oncology Market Size 2023 (US$)
Table23: Companion Diagnostic Tests in Oncology Market Forecast Analysis 2023-2030 (US$)
Table24: Companion Diagnostic Tests in Oncology Market Sales Forecast Analysis 2023-2030 (Units)
Table25: Top Companies 2023 (US$) Companion Diagnostic Tests in Oncology Market, Revenue & Volume
Table26: Product Launch 2023-2030 Companion Diagnostic Tests in Oncology Market, Revenue & Volume
Table27: Mergers & Acquistions 2023-2030 Companion Diagnostic Tests in Oncology Market, Revenue & Volume
List of Figures
Figure 1: Overview of Companion Diagnostic Tests in Oncology Market 2023-2030
Figure 2: Market Share Analysis for Companion Diagnostic Tests in Oncology Market 2023 (US$)
Figure 3: Product Comparison in Companion Diagnostic Tests in Oncology Market 2023-2030 (US$)
Figure 4: End User Profile for Companion Diagnostic Tests in Oncology Market 2023-2030 (US$)
Figure 5: Patent Application and Grant in Companion Diagnostic Tests in Oncology Market 2013-2023* (US$)
Figure 6: Top 5 Companies Financial Analysis in Companion Diagnostic Tests in Oncology Market 2023-2030 (US$)
Figure 7: Market Entry Strategy in Companion Diagnostic Tests in Oncology Market 2023-2030
Figure 8: Ecosystem Analysis in Companion Diagnostic Tests in Oncology Market 2023
Figure 9: Average Selling Price in Companion Diagnostic Tests in Oncology Market 2023-2030
Figure 10: Top Opportunites in Companion Diagnostic Tests in Oncology Market 2023-2030
Figure 11: Market Life Cycle Analysis in Companion Diagnostic Tests in Oncology Market
Figure 12: Global Companion Diagnostic Tests in Oncology Market - By Geography
Figure 13: Global Companion Diagnostic Tests in Oncology Market Value & Volume, By Geography, 2023-2030 ($)
Figure 14: Global Companion Diagnostic Tests in Oncology Market CAGR, By Geography, 2023-2030 (%)
Figure 15: North America Companion Diagnostic Tests in Oncology Market Value & Volume, 2023-2030 ($)
Figure 16: US Companion Diagnostic Tests in Oncology Market Value & Volume, 2023-2030 ($)
Figure 17: US GDP and Population, 2023-2030 ($)
Figure 18: US GDP – Composition of 2023, By Sector of Origin
Figure 19: US Export and Import Value & Volume, 2023-2030 ($)
Figure 20: Canada Companion Diagnostic Tests in Oncology Market Value & Volume, 2023-2030 ($)
Figure 21: Canada GDP and Population, 2023-2030 ($)
Figure 22: Canada GDP – Composition of 2023, By Sector of Origin
Figure 23: Canada Export and Import Value & Volume, 2023-2030 ($)
Figure 24: Mexico Companion Diagnostic Tests in Oncology Market Value & Volume, 2023-2030 ($)
Figure 25: Mexico GDP and Population, 2023-2030 ($)
Figure 26: Mexico GDP – Composition of 2023, By Sector of Origin
Figure 27: Mexico Export and Import Value & Volume, 2023-2030 ($)
Figure 28: South America Companion Diagnostic Tests in Oncology Market Value & Volume, 2023-2030 ($)
Figure 29: Brazil Companion Diagnostic Tests in Oncology Market Value & Volume, 2023-2030 ($)
Figure 30: Brazil GDP and Population, 2023-2030 ($)
Figure 31: Brazil GDP – Composition of 2023, By Sector of Origin
Figure 32: Brazil Export and Import Value & Volume, 2023-2030 ($)
Figure 33: Venezuela Companion Diagnostic Tests in Oncology Market Value & Volume, 2023-2030 ($)
Figure 34: Venezuela GDP and Population, 2023-2030 ($)
Figure 35: Venezuela GDP – Composition of 2023, By Sector of Origin
Figure 36: Venezuela Export and Import Value & Volume, 2023-2030 ($)
Figure 37: Argentina Companion Diagnostic Tests in Oncology Market Value & Volume, 2023-2030 ($)
Figure 38: Argentina GDP and Population, 2023-2030 ($)
Figure 39: Argentina GDP – Composition of 2023, By Sector of Origin
Figure 40: Argentina Export and Import Value & Volume, 2023-2030 ($)
Figure 41: Ecuador Companion Diagnostic Tests in Oncology Market Value & Volume, 2023-2030 ($)
Figure 42: Ecuador GDP and Population, 2023-2030 ($)
Figure 43: Ecuador GDP – Composition of 2023, By Sector of Origin
Figure 44: Ecuador Export and Import Value & Volume, 2023-2030 ($)
Figure 45: Peru Companion Diagnostic Tests in Oncology Market Value & Volume, 2023-2030 ($)
Figure 46: Peru GDP and Population, 2023-2030 ($)
Figure 47: Peru GDP – Composition of 2023, By Sector of Origin
Figure 48: Peru Export and Import Value & Volume, 2023-2030 ($)
Figure 49: Colombia Companion Diagnostic Tests in Oncology Market Value & Volume, 2023-2030 ($)
Figure 50: Colombia GDP and Population, 2023-2030 ($)
Figure 51: Colombia GDP – Composition of 2023, By Sector of Origin
Figure 52: Colombia Export and Import Value & Volume, 2023-2030 ($)
Figure 53: Costa Rica Companion Diagnostic Tests in Oncology Market Value & Volume, 2023-2030 ($)
Figure 54: Costa Rica GDP and Population, 2023-2030 ($)
Figure 55: Costa Rica GDP – Composition of 2023, By Sector of Origin
Figure 56: Costa Rica Export and Import Value & Volume, 2023-2030 ($)
Figure 57: Europe Companion Diagnostic Tests in Oncology Market Value & Volume, 2023-2030 ($)
Figure 58: U.K Companion Diagnostic Tests in Oncology Market Value & Volume, 2023-2030 ($)
Figure 59: U.K GDP and Population, 2023-2030 ($)
Figure 60: U.K GDP – Composition of 2023, By Sector of Origin
Figure 61: U.K Export and Import Value & Volume, 2023-2030 ($)
Figure 62: Germany Companion Diagnostic Tests in Oncology Market Value & Volume, 2023-2030 ($)
Figure 63: Germany GDP and Population, 2023-2030 ($)
Figure 64: Germany GDP – Composition of 2023, By Sector of Origin
Figure 65: Germany Export and Import Value & Volume, 2023-2030 ($)
Figure 66: Italy Companion Diagnostic Tests in Oncology Market Value & Volume, 2023-2030 ($)
Figure 67: Italy GDP and Population, 2023-2030 ($)
Figure 68: Italy GDP – Composition of 2023, By Sector of Origin
Figure 69: Italy Export and Import Value & Volume, 2023-2030 ($)
Figure 70: France Companion Diagnostic Tests in Oncology Market Value & Volume, 2023-2030 ($)
Figure 71: France GDP and Population, 2023-2030 ($)
Figure 72: France GDP – Composition of 2023, By Sector of Origin
Figure 73: France Export and Import Value & Volume, 2023-2030 ($)
Figure 74: Netherlands Companion Diagnostic Tests in Oncology Market Value & Volume, 2023-2030 ($)
Figure 75: Netherlands GDP and Population, 2023-2030 ($)
Figure 76: Netherlands GDP – Composition of 2023, By Sector of Origin
Figure 77: Netherlands Export and Import Value & Volume, 2023-2030 ($)
Figure 78: Belgium Companion Diagnostic Tests in Oncology Market Value & Volume, 2023-2030 ($)
Figure 79: Belgium GDP and Population, 2023-2030 ($)
Figure 80: Belgium GDP – Composition of 2023, By Sector of Origin
Figure 81: Belgium Export and Import Value & Volume, 2023-2030 ($)
Figure 82: Spain Companion Diagnostic Tests in Oncology Market Value & Volume, 2023-2030 ($)
Figure 83: Spain GDP and Population, 2023-2030 ($)
Figure 84: Spain GDP – Composition of 2023, By Sector of Origin
Figure 85: Spain Export and Import Value & Volume, 2023-2030 ($)
Figure 86: Denmark Companion Diagnostic Tests in Oncology Market Value & Volume, 2023-2030 ($)
Figure 87: Denmark GDP and Population, 2023-2030 ($)
Figure 88: Denmark GDP – Composition of 2023, By Sector of Origin
Figure 89: Denmark Export and Import Value & Volume, 2023-2030 ($)
Figure 90: APAC Companion Diagnostic Tests in Oncology Market Value & Volume, 2023-2030 ($)
Figure 91: China Companion Diagnostic Tests in Oncology Market Value & Volume, 2023-2030
Figure 92: China GDP and Population, 2023-2030 ($)
Figure 93: China GDP – Composition of 2023, By Sector of Origin
Figure 94: China Export and Import Value & Volume, 2023-2030 ($) Companion Diagnostic Tests in Oncology Market China Export and Import Value & Volume, 2023-2030 ($)
Figure 95: Australia Companion Diagnostic Tests in Oncology Market Value & Volume, 2023-2030 ($)
Figure 96: Australia GDP and Population, 2023-2030 ($)
Figure 97: Australia GDP – Composition of 2023, By Sector of Origin
Figure 98: Australia Export and Import Value & Volume, 2023-2030 ($)
Figure 99: South Korea Companion Diagnostic Tests in Oncology Market Value & Volume, 2023-2030 ($)
Figure 100: South Korea GDP and Population, 2023-2030 ($)
Figure 101: South Korea GDP – Composition of 2023, By Sector of Origin
Figure 102: South Korea Export and Import Value & Volume, 2023-2030 ($)
Figure 103: India Companion Diagnostic Tests in Oncology Market Value & Volume, 2023-2030 ($)
Figure 104: India GDP and Population, 2023-2030 ($)
Figure 105: India GDP – Composition of 2023, By Sector of Origin
Figure 106: India Export and Import Value & Volume, 2023-2030 ($)
Figure 107: Taiwan Companion Diagnostic Tests in Oncology Market Value & Volume, 2023-2030 ($)
Figure 108: Taiwan GDP and Population, 2023-2030 ($)
Figure 109: Taiwan GDP – Composition of 2023, By Sector of Origin
Figure 110: Taiwan Export and Import Value & Volume, 2023-2030 ($)
Figure 111: Malaysia Companion Diagnostic Tests in Oncology Market Value & Volume, 2023-2030 ($)
Figure 112: Malaysia GDP and Population, 2023-2030 ($)
Figure 113: Malaysia GDP – Composition of 2023, By Sector of Origin
Figure 114: Malaysia Export and Import Value & Volume, 2023-2030 ($)
Figure 115: Hong Kong Companion Diagnostic Tests in Oncology Market Value & Volume, 2023-2030 ($)
Figure 116: Hong Kong GDP and Population, 2023-2030 ($)
Figure 117: Hong Kong GDP – Composition of 2023, By Sector of Origin
Figure 118: Hong Kong Export and Import Value & Volume, 2023-2030 ($)
Figure 119: Middle East & Africa Companion Diagnostic Tests in Oncology Market Middle East & Africa 3D Printing Market Value & Volume, 2023-2030 ($)
Figure 120: Russia Companion Diagnostic Tests in Oncology Market Value & Volume, 2023-2030 ($)
Figure 121: Russia GDP and Population, 2023-2030 ($)
Figure 122: Russia GDP – Composition of 2023, By Sector of Origin
Figure 123: Russia Export and Import Value & Volume, 2023-2030 ($)
Figure 124: Israel Companion Diagnostic Tests in Oncology Market Value & Volume, 2023-2030 ($)
Figure 125: Israel GDP and Population, 2023-2030 ($)
Figure 126: Israel GDP – Composition of 2023, By Sector of Origin
Figure 127: Israel Export and Import Value & Volume, 2023-2030 ($)
Figure 128: Entropy Share, By Strategies, 2023-2030* (%) Companion Diagnostic Tests in Oncology Market
Figure 129: Developments, 2023-2030* Companion Diagnostic Tests in Oncology Market
Figure 130: Company 1 Companion Diagnostic Tests in Oncology Market Net Revenue, By Years, 2023-2030* ($)
Figure 131: Company 1 Companion Diagnostic Tests in Oncology Market Net Revenue Share, By Business segments, 2023 (%)
Figure 132: Company 1 Companion Diagnostic Tests in Oncology Market Net Sales Share, By Geography, 2023 (%)
Figure 133: Company 2 Companion Diagnostic Tests in Oncology Market Net Revenue, By Years, 2023-2030* ($)
Figure 134: Company 2 Companion Diagnostic Tests in Oncology Market Net Revenue Share, By Business segments, 2023 (%)
Figure 135: Company 2 Companion Diagnostic Tests in Oncology Market Net Sales Share, By Geography, 2023 (%)
Figure 136: Company 3 Companion Diagnostic Tests in Oncology Market Net Revenue, By Years, 2023-2030* ($)
Figure 137: Company 3 Companion Diagnostic Tests in Oncology Market Net Revenue Share, By Business segments, 2023 (%)
Figure 138: Company 3 Companion Diagnostic Tests in Oncology Market Net Sales Share, By Geography, 2023 (%)
Figure 139: Company 4 Companion Diagnostic Tests in Oncology Market Net Revenue, By Years, 2023-2030* ($)
Figure 140: Company 4 Companion Diagnostic Tests in Oncology Market Net Revenue Share, By Business segments, 2023 (%)
Figure 141: Company 4 Companion Diagnostic Tests in Oncology Market Net Sales Share, By Geography, 2023 (%)
Figure 142: Company 5 Companion Diagnostic Tests in Oncology Market Net Revenue, By Years, 2023-2030* ($)
Figure 143: Company 5 Companion Diagnostic Tests in Oncology Market Net Revenue Share, By Business segments, 2023 (%)
Figure 144: Company 5 Companion Diagnostic Tests in Oncology Market Net Sales Share, By Geography, 2023 (%)
Figure 145: Company 6 Companion Diagnostic Tests in Oncology Market Net Revenue, By Years, 2023-2030* ($)
Figure 146: Company 6 Companion Diagnostic Tests in Oncology Market Net Revenue Share, By Business segments, 2023 (%)
Figure 147: Company 6 Companion Diagnostic Tests in Oncology Market Net Sales Share, By Geography, 2023 (%)
Figure 148: Company 7 Companion Diagnostic Tests in Oncology Market Net Revenue, By Years, 2023-2030* ($)
Figure 149: Company 7 Companion Diagnostic Tests in Oncology Market Net Revenue Share, By Business segments, 2023 (%)
Figure 150: Company 7 Companion Diagnostic Tests in Oncology Market Net Sales Share, By Geography, 2023 (%)
Figure 151: Company 8 Companion Diagnostic Tests in Oncology Market Net Revenue, By Years, 2023-2030* ($)
Figure 152: Company 8 Companion Diagnostic Tests in Oncology Market Net Revenue Share, By Business segments, 2023 (%)
Figure 153: Company 8 Companion Diagnostic Tests in Oncology Market Net Sales Share, By Geography, 2023 (%)
Figure 154: Company 9 Companion Diagnostic Tests in Oncology Market Net Revenue, By Years, 2023-2030* ($)
Figure 155: Company 9 Companion Diagnostic Tests in Oncology Market Net Revenue Share, By Business segments, 2023 (%)
Figure 156: Company 9 Companion Diagnostic Tests in Oncology Market Net Sales Share, By Geography, 2023 (%)
Figure 157: Company 10 Companion Diagnostic Tests in Oncology Market Net Revenue, By Years, 2023-2030* ($)
Figure 158: Company 10 Companion Diagnostic Tests in Oncology Market Net Revenue Share, By Business segments, 2023 (%)
Figure 159: Company 10 Companion Diagnostic Tests in Oncology Market Net Sales Share, By Geography, 2023 (%)
Figure 160: Company 11 Companion Diagnostic Tests in Oncology Market Net Revenue, By Years, 2023-2030* ($)
Figure 161: Company 11 Companion Diagnostic Tests in Oncology Market Net Revenue Share, By Business segments, 2023 (%)
Figure 162: Company 11 Companion Diagnostic Tests in Oncology Market Net Sales Share, By Geography, 2023 (%)
Figure 163: Company 12 Companion Diagnostic Tests in Oncology Market Net Revenue, By Years, 2023-2030* ($)
Figure 164: Company 12 Companion Diagnostic Tests in Oncology Market Net Revenue Share, By Business segments, 2023 (%)
Figure 165: Company 12 Companion Diagnostic Tests in Oncology Market Net Sales Share, By Geography, 2023 (%)
Figure 166: Company 13 Companion Diagnostic Tests in Oncology Market Net Revenue, By Years, 2023-2030* ($)
Figure 167: Company 13 Companion Diagnostic Tests in Oncology Market Net Revenue Share, By Business segments, 2023 (%)
Figure 168: Company 13 Companion Diagnostic Tests in Oncology Market Net Sales Share, By Geography, 2023 (%)
Figure 169: Company 14 Companion Diagnostic Tests in Oncology Market Net Revenue, By Years, 2023-2030* ($)
Figure 170: Company 14 Companion Diagnostic Tests in Oncology Market Net Revenue Share, By Business segments, 2023 (%)
Figure 171: Company 14 Companion Diagnostic Tests in Oncology Market Net Sales Share, By Geography, 2023 (%)
Figure 172: Company 15 Companion Diagnostic Tests in Oncology Market Net Revenue, By Years, 2023-2030* ($)
Figure 173: Company 15 Companion Diagnostic Tests in Oncology Market Net Revenue Share, By Business segments, 2023 (%)
Figure 174: Company 15 Companion Diagnostic Tests in Oncology Market Net Sales Share, By Geography, 2023 (%)